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1997), presentation of L. major antigens
to CD8þ T cells appears to be indepen-
dent of these two major nonlyso-
somal protein degradation machineries,
implying the involvement of alternative
cytosolic pathways of cross-presentation
emcompassing protease candidates, such
as tripeptidyl peptidase II and nardilysin.
In summary, our data indicate that
despite the fact that CD8 responses are
highly effective in protecting against nat-
ural L. major infections, it remains unclear
how parasite epitopes are generated in
infected DC. Interestingly, recent data
suggest that priming of Leishmania-specific
CD4þ T cells is mediated by Langerinneg
dermal DCs, whereas Langerinþ dermal
DCs promote early CD8þ T-cell priming
(Brewig et al., 2009). A detailed under-
standing of the pathways utilized for pro-
cessing of L. major-derived CTL-epitopes
in the MHC class I pathway as well as
knowing which DC subset to target during
vaccination will be helpful for the devel-
opment of new vaccine candidates against
this important human pathogen.
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TO THE EDITOR
Epidermodysplasia verruciformis (EV) is
a rare, lifelong, autosomal recessive
skin disease (OMIM number 226400)
associated with an unusual susceptibil-
ity to infections with ubiquitous beta
human papillomaviruses (b-HPVs), but
not to infections with other pathogens,
including cutaneous and genital HPVs
of the alpha, gamma, mu, or nu genera
(Jablonska and Majewski, 1994; Orth,
2006).Abbreviations: EV, epidermodysplasia verruciformis; HPV, human papillomavirus
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b-HPVs are evolutionarily distinct
from the other HPV genera and are
associated with widespread in-apparent
or asymptomatic infections in the gen-
eral population (Bernard et al., 2010;
Bravo et al., 2010). In immunosup-
pressed individuals, however, and in
individuals suffering from the rare
inherited disease EV, these viruses can
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Figure 1. Clinical, histological, virological, and genetic findings from the epidermodysplasia verruciformis (EV) study patients. Forehead regions of EV patient
4 (EVpt4) (a) and EVpt5 (b) showing erythematous and hyperkeratotic plaques. Biopsy specimens from Bowen’s disease lesions (c, EVpt4; d, EVpt5) demonstrate
typical histological features of EV. Bar¼100 mm. Human papillomavirus (HPV) genotyping in eyebrow hair bulbs is reported for each patient below the
forehead images. The viral load values, expressed as DNA copy number per cell, are shown in brackets. na, not available. (e) The automated sequencing
of the PCR fragments derived from the EVER2 gene revealed a 13-nucleotide deletion, g.6609_6621delACTTCACCTTCCT in exon 4 in EVpt4. The deletion
is predicted to change the reading frame and result in a premature stop codon (PTC) after nine amino acids (p.Y109fsX118). (f) In patient 5, a single-nucleotide
deletion was detected in exon 6 of EVER2 (g.7668delG), which is predicted to change the reading frame and result in a PTC in exon 7 (p.V191fsX226).
(g) Schematic representation of the WT EVER2 gene with indication of the mutations detected in the two study patients. The encoded WT protein along
with the variant proteins, as predicted by computational analysis, is also shown. Green boxes represent the altered protein encoded after deletion,
which was interrupted downstream by the predicted PTC. (h) Lysates (30 mg) collected from EV-derived keratinocytes and healthy donors (Ctrl) were analyzed
by western blot for levels of the EVER2 protein. Antibodies were generated against the first 80 amino acids of EVER2 as described in the Supplementary
Information online. b-Actin served as a loading control.
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replicate unchecked and have been
implicated in the development of non-
melanoma skin cancer (Akgul et al.,
2006; Bouwes Bavinck et al., 2011;
Proby et al., 2011).
The sensitivity of EV patients to
b-HPVs has been linked to homozygous
mutations in two genes (EVER1 and
EVER2; Ramoz et al., 2002). The muta-
tion of either of the EVER genes holds the
potential to alleviate EVER-mediated host
restriction and favor b-HPV replication
and skin carcinogenesis, as is the case in
EV patients (Lazarczyk et al., 2009).
In this report, we describe the
presence of two previously unreported
homozygous mutations in the EVER2
gene in two Italian EV patients, each of
whom have already developed more
than 10 non-melanoma skin cancer.
EV patient 4 (EVpt4) has been
previously described by our group
(Dell’Oste et al., 2009) and his clinical
picture is presented in Figure 1a.
EV patient 5 (EVpt5) is a 58-year-old
male who was referred to our hospital
with a diagnosis of EV in 2009. Since
the age of 42 years, he has had 12
tumors resectioned from his face (fore-
head; Figure 1b) and back. HPV14 was
consistently found in all lesions (CB and
MG, manuscript in preparation). HPV
DNA analysis of plucked eyebrow
hairs revealed the presence of multiple
HPV genotypes of the b-genus, with
HPV5 and HPV14 viral loads being
the highest (Figures 1a and b, below
the forehead images). Both patients
are HIV-negative. As shown in the
representative Bowen’s disease tumor
sections in Figures 1c and d, the
unequivocal histological features of EV
(defined by acanthosis containing a
majority of cells that show perinuclear
halos and blue–gray pallor) are present
in both patients’ tumors.
Genomic DNA extracted from blood
samples of both patients was used to
perform genetic analysis of the EVER1
and EVER2 genes (see Supplementary
Information online). In these patients,
no mutations were detected in the
EVER1 gene, while they harbor novel
invalidating deletions in the EVER2
gene, which create shifts in the reading
frame and introduce a premature termi-
nation codon as shown in Figure 1e
and f. Neither of these frameshift
mutations had previously been reported
in EV. We confirmed the lack of the
EVER2 protein by western blot analysis.
As shown in Figure 1h, lysates obtained
from keratinocytes isolated from the
patients lacked a protein of about
85 kDa, the molecular weight expected
for the EVER2 protein, which was
present in keratinocytes obtained from
healthy donors. No extra bands with
lower molecular weight were detected
in EV patients’ extracts, indicating that
production of the predicted truncated
proteins (Figure 1g) did not occur as
a consequence of premature termina-
tion codon introduction but rather
transcripts are eliminated by nonsense-
mediated RNA degradation (Bhuvanagiri
et al., 2010).
EVpt4 has consanguineous parents
(they were first cousins). He is married
to a healthy, unrelated woman, has a
son and a daughter, who are both
unaffected, and has a brother who is
unaffected. To verify the presence of
the 13 nucleotide deletion detected in
EVpt4, the genomic DNA extracted
from blood samples of all of his family
members was amplified by exon 4–spe-
cific primers and analyzed by agarose
gel electrophoresis with high resolu-
tion. As shown in Figure 2, both parents
carried the 13 nucleotide deletion in
the heterozygous state, but not inher-
ited by the other sibling. In contrast,
both the proband’s son and daughter
inherited the mutated allele in the
heterozygous state.
HPV–DNA genotyping and deter-
mination of DNA copy numbers by
type-specific Q-PCR protocols were per-
formed with DNA extracted from the
plucked eyebrows of all family members
(see Supplementary Information online).
Some of the genotypes present in
the proband were consistently found
in all family members, including HPV5
and 20. Of note, the HPV5 viral load
in his mother was 15 DNA copies per
cell. This finding is consistent with
the predominant high viral load for
HPV5 reported in all five EV patients
enrolled by our group (Azzimonti et al.,
2005; Zavattaro et al., 2008; Dell’Oste
et al., 2009) and suggests that even in
the heterozygous genetic background
HPV5 replication may be favored by a
reduction in EVER2 protein availability.
HPV5 and 20 are highly persistent in
this family, despite the fact that the
family members are of very different
ages and live in different houses. The
presence of HPV5 with a viral load of
four DNA copies per cell in his wife
suggests that close and frequent skin
contacts with an individual carrying
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Figure 2. Genetic status and detection of beta human papillomavirus (b-HPV) DNA in epidermodys-
plasia verruciformis (EV) patient 4 (EVpt4)’s family members. The pedigree of EVpt4’s family is
shown together with b-HPV carriage in eyebrows hair bulbs of each individual. The viral load values
expressed, as DNA copy number per cell, are shown in curved brackets or not reported when they
were less than one copy per cell. Squares and circles indicate males and females, respectively, with
years of birth given underneath. Double lines are indicative of consanguineous unions. Filled symbols
indicate the homozygous genotype and half-filled symbols indicate the heterozygous genotype of
the EVER2 gene deletion. The arrow indicates the proband.
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high viral loads for a certain geno-
type can facilitate virus transmission
and sharing of such specific genotype
between family members.
This report describes a correlation
between genetic status and b-HPV
carriage in EV family members; to our
knowledge this is previously unre-
ported. Collectively, our findings
strengthen the hypothesis that the
EVER2 gene has a crucial role in the
development of EV and in susceptibility
to specific b-HPV genotypes. The de-
tection of HPV5 and 20, both of which
belong to the b1 species, in all family
members, confirms that infection by
these subsets of b genotypes is favored
by the EV genetic background and is
passed between individuals via skin
contact (Weissenborn et al., 2009).
Following the pioneering work by
Ramoz et al. (2002), which showed
frameshift mutations in the EVER2 gene
in an Algerian/Colombian consangui-
neous EV family, this is the second
report to demonstrate an EVER2 auto-
somal recessive trait in EV. Another
three studies have described nonsense
mutations in the EVER2 gene: a Chinese
EV patient born from consanguineous
parents (Sun et al., 2005), three siblings
from a Brazilian family (Rady et al.,
2007), and a Hispanic man (Berthelot
et al., 2007). Here, we demonstrate two
previously unreported deletions, in
exons 4 and 6, respectively, in two
Italian EV patients. In one patient, we
also show that the EVER2 deletion
was carried in the heterozygous state
by his parents and inherited in an
heterozygous manner by his children.
This study provides additional evi-
dence indicating that the lack of the
EVER2 protein favors the infection and
persistence of specific b1 genotypes, in
particular, HPV5, which is often the
type presenting the highest viral loads
in EV hair bulbs. In addition, the
findings of this study strengthen the
notion that EVER2 is a key host factor in
controlling b-HPV infection and virus-
induced skin carcinogenesis in EV
patients.
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